Skip to main content

pegvisomant (Somavert®)

 

Status: Recommended

Pegvisomant (Somavert®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise insulin-like growth factor-1 (IGF-1) concentrations or was not tolerated. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

 Final Recommendation: pegvisomant (Somavert) 3545 (PDF, 307Kb)
 Appraisal Report: pegvisomant (Somavert) 3545 (PDF, 357Kb)

Medicine details

Medicine name pegvisomant (Somavert®)
Formulation 10 mg, 15 mg, 20 mg, 25 mg, 30 mg powder and solvent for solution for injection
Reference number 3545
Indication

Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise insulin-like growth factor-1 (IGF-1) concentrations or was not tolerated

Company Pfizer Ltd
BNF chapter Endocrine system
Submission type Resubmission
Status Recommended
Advice number 2417
NMG meeting date 04/10/2017
AWMSG meeting date 08/11/2017
Date of issue 28/11/2017
Date of last review November 2020
Commercial arrangement WPAS